Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women

Alison Edelman; Jeffrey T. Jensen; Carmen M. Doom; Jon D. Hennebold

doi:10.1016/j.contraception.2012.07.004

Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women

Alison Edelman, Jeffrey T. Jensen, Carmen M. Doom, Jon D. Hennebold

In: Contraception · 2012 · vol. 87(3) , pp. 352–357 · doi:10.1016/j.contraception.2012.07.004 · PMID:22902348 · W2020419604

article OA: closed CC0 ⤵ 1 in-corpus citation

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-11 ⓘ

This study investigated the effects of the COX-2 inhibitor celecoxib on ovulation and subsequent luteal phase events in women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study 2001

Cited by (1)

Evaluation of the effect of using NSAIDs on ovulation in women during reproductive age: a case control study 2019

References (28)

Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study via openalex
doi:10.7326/0003-4819-109-2-176_1 via openalex
doi:10.1210/jcem-66-5-909 via openalex
doi:10.1016/j.contraception.2004.05.007 via openalex
doi:10.1161/circresaha.108.192526 via openalex
doi:10.1074/jbc.m608202200 via openalex
doi:10.1001/jama.1988.03410200127050 via openalex
doi:10.1210/endo-123-5-2261 via openalex
doi:10.1016/j.contraception.2010.01.004 via openalex
doi:10.1210/me.2007-0484 via openalex
doi:10.1093/humrep/deq157 via openalex
doi:10.1093/humrep/del369 via openalex
doi:10.1210/en.2003-1607 via openalex
W6630657919 via openalex
doi:10.1016/s0140-6736(10)60101-8 via openalex
doi:10.1210/jcem-55-1-102 via openalex
doi:10.1177/0091270006289483 via openalex
doi:10.1095/biolreprod43.3.507 via openalex
doi:10.1124/dmd.105.006452 via openalex
doi:10.1093/humrep/17.11.2825 via openalex
doi:10.1093/humrep/dep392 via openalex
doi:10.1093/humrep/dep424 via openalex
doi:10.1095/biolreprod.102.008425 via openalex
doi:10.1210/en.2008-0500 via openalex
doi:10.1095/biolreprod20.4.897 via openalex
doi:10.1016/b978-0-12-397175-3.00023-5 via openalex
doi:10.1038/378406a0 via openalex
doi:10.1007/978-94-010-2351-1_3 via openalex

Cited by (1)

Evaluation of the effect of using NSAIDs on ovulation in women during reproductive age: a case control study 2019

Source provenance

openalex: last seen: 2026-05-14T06:09:40.812857+00:00
unpaywall: last seen: 2026-06-02T02:00:03.124865+00:00

License: CC0 · commercial use OK

[1] Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study 2001